Intrasphincteric injections of autologous muscular cells in women with refractory stress urinary incontinence: a prospective study

Sèbe, Philippe; Doucet, Christelle; Cornu, Jean‐Nicolas; Ciofu, C.; Costa, P.; Medina, Sixtina Gil Diez de; Pinset, Christian; Haab, F.

doi:10.1007/s00192-010-1255-5

Cited by 88 publications

(83 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the efficacy results differ widely, as the methodology used for studies was very different, as described below. All studies were phase II prospective observational studies, except for 2 randomized studies [1,2], in which patients were randomized to different doses of stem cells.…”

Section: Resultsmentioning

confidence: 99%

“…All studies excluded urge incontinence or abnormal detrusor activity except for the study by Lee [5], which included 9 patients with mixed UI. However, in SUI, some only required that the patient had stress urinary incontinence (regardless of severity) [2,5,7,8] whereas others include only patients with SUI due to inherent sphincter weakness or at least exclude patients with urethral hypermobility > 45⁰ [1,3,9,10]. Nonetheless, it appears that the purpose of stem cells is to regenerate damaged sphincters, rather than to provide urethral support; in fact, some studies exclude patients with prolapse [2,4,9].…”

Section: Inclusion Criteria Of Patients In Studies For the Treatment mentioning

confidence: 99%

See 1 more Smart Citation

Current Controversies in Stem-Cell Treatment of Urinary Incontinence in Women

Ferrer¹,

Machado-Linde²,

Prieto-Sánchez³

et al. 2014

Int J Gynecol Clin Pract

View full text Add to dashboard Cite

Background: Urinary incontinence (UI) is a major cause of morbidity in the world and is believed to affect up to 46% of the female population Our objective was to analyze the papers that describe stem-cell treatments for UI in women. Methods: We performed a systematic review of the literature from 1946 to date that reports on clinical trials that use stem cells to treat women with urinary incontinence. Results: Nine articles (7 observational and 2 randomized studies) met the inclusion criteria. No major adverse effects were observed in any of the studies. However, the efficacy results differ widely, as the methodology used for studies was very different, as described below. Conclusion: Stem-cell therapy is promising but still experimental, and further study is needed to identify certain factors. These facts include the ideal type of patient eligible for treatment (apparently those in whom intrinsic urethral dysfunction predominates), and to determine if treatment should be isolated or combined with other cells or procedures, which are the optimal doses and if it is a cost effective procedure.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Inclusion Criteria Of Patients In Studies For the Treatment mentioning

confidence: 99%

Current Controversies in Stem-Cell Treatment of Urinary Incontinence in Women

Ferrer¹,

Machado-Linde²,

Prieto-Sánchez³

et al. 2014

Int J Gynecol Clin Pract

View full text Add to dashboard Cite

show abstract

“…So far, the cells used for injection in human studies have been autologous myoblasts with or without fibroblasts, muscle-derived stem cells, muscle-derived cells, and umbilical cord blood stem cells [79]. The reported success rates are 50-100%, although followup is short-term and less than 1 year [80][81][82]. A recent study of 12 women with severe SUI with fixed urethra and previous failed surgery showed that intrasphincteric injections of autologous progenitor muscular cells isolated from a biopsy of the deltoid muscle are feasible and safe as a second-line treatment [81].…”

Section: Cell-based Therapymentioning

confidence: 99%

“…The reported success rates are 50-100%, although followup is short-term and less than 1 year [80][81][82]. A recent study of 12 women with severe SUI with fixed urethra and previous failed surgery showed that intrasphincteric injections of autologous progenitor muscular cells isolated from a biopsy of the deltoid muscle are feasible and safe as a second-line treatment [81]. In this study, 3 of 12 patients were dry at 12 months, 7 other patients were improved on pad test but not on voiding diary, and 2 patients were slightly worsened by the procedure.…”

Section: Cell-based Therapymentioning

confidence: 99%

Recent Developments in the Surgical Management of Urinary Stress Incontinence

Ahn

Alvarez

Dwyer

2013

Curr Obstet Gynecol Rep

View full text Add to dashboard Cite

Surgical management continues to be the mainstay of treatment for patients with moderate to severe stress urinary incontinence who are nonresponsive to conservative measurements. In the past, the Burch colposuspension was considered the first line of treatment; however, since the introduction of mid-urethral slings in the mid 1990s the retropubic sling has become the "gold standard." Tension-free vaginal tape (TVT) is the original retropubic procedure with good long-term efficacy and safety data available. However, in an attempt to decrease the risk of retropubic complications, such as vascular, bowel, or bladder injury, the transobturator and single incision minislings have been described. In this review, we give an overview on the recent data available on conventional anti-incontinence procedures as well as other more recently developed procedures. Recent studies with more than 10 years of follow-up continue to confirm the effectiveness of the TVT sling in the long-term, which the other approaches need to match.

show abstract

“…(Mitterberger et al 2008;Sebe et al 2011) In the human studies, myoblasts and fibroblasts were obtained from muscle biopsies of the patient. Cells are then grown in a culture facility to yield more myoblasts.…”

Section: New Technologiesmentioning

confidence: 99%